Melola Discovery

← Melola Discovery

Jurnal SINTA 1

Recombinant vascular endothelial growth factor 121 decreases vascular cell adhesion molecule-1 in murine pre-eclampsia model placenta

Universa Medicina · Vol. 35 No. 3 (2016) · hlm. 192–198

DOI
10.18051/UnivMed.2016.v35.192-198
ISSN
2407-2230, 1907-3062
Terbit
2016-11-30
Penerbit
Faculty of Medicine, Universitas Trisakti
Bahasa
eng

Abstrak

BackgroundPreeclampsia is one of the major contributors to maternal and fetal morbidity and mortality. Imbalance of soluble Fms-like tyrosine kinase (sFlt-1) as anti-angiogenic factor and vascular endothelial growth factor (VEGF) as pro-angiogenic factor plays a role in the pathogenesis of preeclampsia. Endothelial dysfunction in preeclampsia causes vascular cell adhesion molecule-1 (VCAM-1) to be expressed on its surface. This study aims to evaluate the effect of recombinant VEGF-121 on VCAM-1 expression in the placenta of a murine preeclampsia model. Methods An experimental analytical study conducted from February until March 2016 in the Biomedical Laboratory, Faculty of Veterinary Medicine, Airlangga University. The study sample consisted of 30 pregnant mice, divided into three groups, i.e. 10 normal pregnant mice, 10 mice with preeclampsia model and 10 mice with preeclampsia model and recombinant VEGF-121 therapy. All animals were subjected to immunohistochemical examination of VCAM-1 expression in their placentas. The results were assessed semiquantitatively according to a modified Remmele method. Data analysis was done using one-way ANOVA and Tukey’s multiple comparisons method. ResultsMean VCAM-1 expression in normal (0.97 ± 0.54%) murine placentas, compared with placentas (2.94 ± 0.96%) of murine preeclampsia models (p=0.000), while mean VCAM-1 expression in placentas of murine preeclampsia models with VEGF intervention was 2.14 ± 0.68% (p=0.030).Conclusion Recombinant VEGF-121 can reduce VCAM-1 expression in placentas of murine preeclampsia models. The present study has shown the potential benefits of VEGF therapy, justifying serious consideration of this therapeutic approach for use in women with preeclampsia.

Kata kunci

Jaringan kolaborasi para penulis

22 penulis · 50 tautan kepenulisan bersama · 6 lintas organisasi

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • Sebelas Maret University
  • Universitas Syiah Kuala
  • Universitas Muhammadiyah Surabaya
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Soetrisno SoetrisnoSebelas Maret University4
Uki Retno BudihastutiSebelas Maret University3
Sultoni Emillya AnggraeniSebelas Maret University2
Bambang Triono CahyadiSebelas Maret University2
Fitriana FitrianaUniversitas Syiah Kuala2
Dono IndartoSebelas Maret University2
Anwar Sandi WibowoSebelas Maret University2
Debree SeptiawanSebelas Maret University2
Risang BhaskoroSebelas Maret University2
Rachmawati Ika SukarsihUniversitas Muhammadiyah Surabaya1
Sabja AnantanyuSebelas Maret University1
Anik LestariSebelas Maret University1
Yuniarsih ZakiaSebelas Maret University1
Soetrisno KhasanSebelas Maret University1
Eriana MelinawatiSebelas Maret University1
Yohan Pamuji MarbunSebelas Maret University1
Nutria Widya Purna AnggrainiSebelas Maret University1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OAI-PMH (metadata jurnal) https://univmed.org/ejurnal/index.php/medicina/oai, pertama di-harvest 10 Nov 2026, terakhir terlihat 16 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Recombinant vascular endothelial growth factor 121  decreases vascular cell adhesion molecule-1 in murine pre-eclampsia model placenta</dc:title>
	<dc:creator xml:lang="en">Sulistyowati, Sri</dc:creator>
	<dc:creator xml:lang="en">Sondakh, John Arianto</dc:creator>
	<dc:creator xml:lang="en">Yuliantara, Eric Edwin</dc:creator>
	<dc:creator xml:lang="en">Respati, Supriyadi Hari</dc:creator>
	<dc:creator xml:lang="en">Soetrisno, Soetrisno</dc:creator>
	<dc:subject xml:lang="en">Recombinant VEGF-121</dc:subject>
	<dc:subject xml:lang="en">VCAM-1</dc:subject>
	<dc:subject xml:lang="en">preeclampsia</dc:subject>
	<dc:subject xml:lang="en">pregnant murine</dc:subject>
	<dc:description xml:lang="en">BackgroundPreeclampsia is one of the major contributors to maternal and fetal morbidity and mortality. Imbalance of soluble Fms-like tyrosine kinase (sFlt-1) as anti-angiogenic factor and vascular endothelial growth factor (VEGF) as pro-angiogenic factor plays a role in the pathogenesis of preeclampsia. Endothelial dysfunction in preeclampsia causes vascular cell adhesion molecule-1 (VCAM-1) to be expressed on its surface. This study aims to evaluate the effect of recombinant VEGF-121 on VCAM-1 expression in the placenta of a murine preeclampsia model. Methods An experimental analytical study conducted from February until March 2016 in the Biomedical Laboratory, Faculty of Veterinary Medicine, Airlangga University. The study sample consisted of 30 pregnant mice, divided into three groups, i.e. 10 normal pregnant mice, 10 mice with preeclampsia model and 10 mice with preeclampsia model and recombinant VEGF-121 therapy. All animals were subjected to immunohistochemical examination of VCAM-1 expression in their placentas. The results were assessed semiquantitatively according to a modified Remmele method. Data analysis was done using one-way ANOVA and Tukey’s multiple comparisons method. ResultsMean VCAM-1 expression in normal (0.97 ± 0.54%) murine placentas, compared with placentas (2.94 ± 0.96%) of murine preeclampsia models (p=0.000), while mean VCAM-1 expression in placentas of murine preeclampsia models with VEGF intervention was 2.14 ± 0.68% (p=0.030).Conclusion Recombinant VEGF-121 can reduce VCAM-1 expression in placentas of murine preeclampsia models. The present study has shown the potential benefits of VEGF therapy, justifying serious consideration of this therapeutic approach for use in women with preeclampsia.</dc:description>
	<dc:publisher xml:lang="en">Faculty of Medicine, Universitas Trisakti</dc:publisher>
	<dc:date>2016-11-30</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://univmed.org/ejurnal/index.php/medicina/article/view/360</dc:identifier>
	<dc:identifier>10.18051/UnivMed.2016.v35.192-198</dc:identifier>
	<dc:source xml:lang="en">Universa Medicina; Vol. 35 No. 3 (2016); 192-198</dc:source>
	<dc:source>2407-2230</dc:source>
	<dc:source>1907-3062</dc:source>
	<dc:source>10.18051/UnivMed.2016.v35.i3</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://univmed.org/ejurnal/index.php/medicina/article/view/360/373</dc:relation>
	<dc:relation>10.18051/univmed.v35i3.360</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2016 Sri Sulistyowati, John Arianto Sondakh, Eric Edwin Yuliantara, Supriyadi Hari Respati, Soetrisno Soetrisno</dc:rights>
</oai_dc:dc>